Apyx Medical Corporation
HealthcareNASDAQ:APYX · NASDAQ Global Select
+$0.04 today
Vol 0.16M · Avg 0.18M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$55.9M of revenue converted into -$9.2M of net income for the selected period. Gross margin is 38.4% and net margin is -18.1%, showing how much revenue survives after costs and taxes. EPS is $-0.22, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $52.8M +9.9% | $48.1M -8.1% | $52.3M +17.6% | $44.5M -8.3% | $48.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $33.8M +80.4% | $18.7M +0.8% | $18.6M +20.9% | $15.4M +3.1% | $14.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $19.0M -35.2% | $29.4M -13.0% | $33.8M +15.9% | $29.1M -13.3% | $33.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 36.0% -25.0pp | 61.0% -3.5pp | 64.5% -1.0pp | 65.4% -3.8pp | 69.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $3.4M -33.6% | $5.1M +4.9% | $4.8M +6.6% | $4.5M +5.2% | $4.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $36.1M -16.3% | $43.1M -11.7% | $48.9M +1.5% | $48.1M +10.1% | $43.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $25.5M -47.1% | $48.2M -5.5% | $51.0M -3.2% | $52.7M +9.7% | $48.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $655.0K +9.3% | $599.0K -13.4% | $692.0K -22.2% | $890.0K -1.4% | $903.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$4.6M +72.7% | -$16.8M +7.2% | -$18.1M +17.7% | -$22.0M -58.2% | -$13.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -8.7% +26.2pp | -34.9% -0.3pp | -34.6% +14.8pp | -49.4% -20.8pp | -28.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$6.4M +65.8% | -$18.8M -9.2% | -$17.3M +26.8% | -$23.6M -63.1% | -$14.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -12.2% +27.0pp | -39.2% -6.2pp | -33.0% +20.0pp | -52.9% -23.2pp | -29.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.1M -31.0% | $1.6M +74.4% | $921.0K +486.6% | $157.0K +1327.3% | $11.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $5.6M -5.4% | $5.9M +138.4% | $2.5M +16420.0% | $15.0K +50.0% | $10.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$4.4M +1.6% | -$4.5M -10.9% | -$4.0M -718.0% | $651.0K +275.0% | -$372.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$10.8M +53.5% | -$23.3M -9.5% | -$21.3M +7.1% | -$22.9M -54.6% | -$14.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -20.5% +27.9pp | -48.5% -7.8pp | -40.7% +10.8pp | -51.5% -20.9pp | -30.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $270.0K +7.1% | $252.0K +110.4% | -$2.4M -762.7% | $367.0K -3.4% | $380.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$11.2M +52.2% | -$23.5M -25.4% | -$18.7M +19.3% | -$23.2M -52.8% | -$15.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -21.2% +27.6pp | -48.8% -13.0pp | -35.7% +16.3pp | -52.1% -20.8pp | -31.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +59.1% | -$1 -22.2% | -$1 +19.4% | -$1 -52.3% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +59.1% | -$1 -22.2% | -$1 +19.4% | -$1 -52.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $42.2M +18.6% | $35.5M +2.7% | $34.6M +0.3% | $34.5M +0.5% | $34.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $42.2M +18.6% | $35.5M +2.7% | $34.6M +0.3% | $34.5M +0.5% | $34.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Pro-Dex, Inc.
NASDAQ:PDEX
$198.59M
Quipt Home Medical Corp.
QIPT
$162.30M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
AVITA Medical, Inc.
NASDAQ:RCEL
$97.14M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
Sera Prognostics, Inc.
NASDAQ:SERA
$71.42M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
Xtant Medical Holdings, Inc.
AMEX:XTNT
$61.72M
InspireMD, Inc.
NSPR
$34.19M
Atossa Therapeutics, Inc.
ATOS
$21.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does APYX generate?
Apyx Medical Corporation (APYX) reported $52.84M of revenue in fiscal 2025.
Is APYX profitable?
Apyx Medical Corporation (APYX) reported -$11,211,000.00 of net income, with a net margin of -21.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.